Free Trial
→ Wall Street legend: “Put $1,000 in this AI stock” (From Chaikin Analytics) (Ad)tc pixel Free MRNA Stock Alerts

Moderna (MRNA) Stock Forecast & Price Target

Moderna logo
$24.64 +0.17 (+0.69%)
As of 10:41 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare

Moderna - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Hold
Based on 24 Analyst Ratings
Sell
4
Hold
16
Buy
4

Based on 24 Wall Street analysts who have issued ratings for Moderna in the last 12 months, the stock has a consensus rating of "Hold." Out of the 24 analysts, 4 have given a sell rating, 16 have given a hold rating, 3 have given a buy rating, and 1 has given a strong buy rating for MRNA.

Consensus Price Target

$42.88
74.04% Upside
According to the 24 analysts' twelve-month price targets for Moderna, the average price target is $42.88. The highest price target for MRNA is $70.00, while the lowest price target for MRNA is $15.00. The average price target represents a forecasted upside of 74.04% from the current price of $24.64.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for MRNA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Moderna and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MRNA Analyst Ratings Over Time

TypeCurrent Forecast
9/10/24 to 9/10/25		1 Month Ago
8/11/24 to 8/11/25		3 Months Ago
6/12/24 to 6/12/25		1 Year Ago
9/11/23 to 9/10/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
7 Buy rating(s)
Hold
16 Hold rating(s)
16 Hold rating(s)
15 Hold rating(s)
10 Hold rating(s)
Sell
4 Sell rating(s)
4 Sell rating(s)
4 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$42.88$43.59$53.58$123.79
Forecasted Upside74.04% Upside71.14% Upside95.90% Upside56.14% Upside
Consensus RatingHoldHoldHoldHold

MRNA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MRNA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Moderna Stock vs. The Competition

TypeModernaMedical CompaniesS&P 500
Consensus Rating Score
2.04
2.78
2.53
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside75.24% Upside16,834.67% Upside10.92% Upside
News Sentiment Rating
Positive News

See Recent MRNA News
Positive News
Positive News
Export to Excel
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
8/22/2025Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Mani Foroohar
Not Rated
Lower TargetUnderperform$18.00 ➝ $15.00-45.68%
8/4/2025Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Gena Wang
Gena Wang
Not Rated
Lower TargetEqual Weight$40.00 ➝ $31.00+13.20%
8/1/2025Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Cory Kasimov
Cory Kasimov
Not Rated
Set Target$32.00+8.25%
8/1/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Jessica Fye
Jessica Fye
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Set Target$26.00-12.04%
8/1/2025Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Geoff Meacham
Geoff Meacham
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Initiated CoverageNeutral$40.00+35.32%
8/1/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Matthew Harrison
Matthew Harrison
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Reiterated RatingEqual Weight$32.00+8.25%
7/22/2025Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Dimple Gosai
Dimple Gosai
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Lower TargetUnderperform$26.00 ➝ $25.00-22.36%
7/13/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Reiterated RatingEqual Weight
7/13/2025Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Initiated CoverageHold
6/2/2025William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Reiterated RatingMarket Perform
5/2/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Eliana Merle
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Lower TargetBuy$78.00 ➝ $70.00+153.53%
5/2/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Luca Issi
Luca Issi
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Lower TargetSector Perform$32.00 ➝ $28.00+1.67%
1/29/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Salveen Richter
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
DowngradeBuy ➝ Neutral$99.00 ➝ $51.00+13.48%
1/16/2025Berenberg Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
H. Gillis
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Boost TargetHold$33.00 ➝ $42.00+24.46%
12/18/2024Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
J. Hellweg
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
DowngradeBuy ➝ Hold
11/18/2024Hsbc Global Res
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Y. Liu
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
11/18/2024Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Reiterated RatingOverweight$115.00 ➝ $69.00+76.83%
11/18/2024HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 UpgradeHold ➝ Buy$58.00+57.39%
11/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
A. Hammond
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Initiated CoverageUnderperform$40.00+0.58%
11/8/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Reiterated RatingHold
10/17/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
C. Breen
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
Initiated CoverageMarket Perform$55.00-4.28%
10/15/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Lower TargetHold$65.00 ➝ $55.00-4.75%
9/13/2024TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Lower TargetHold$70.00 ➝ $60.00-9.92%
9/13/2024Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 DowngradeOutperform ➝ Market Perform
8/7/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 UpgradeSell ➝ Hold$85.00 ➝ $80.00-2.79%
5/3/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Boost TargetHold$91.00 ➝ $106.00-15.20%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 10:41 AM ET.


Should I Buy Moderna Stock? MRNA Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, September 7, 2025. Please send any questions or comments about these Moderna pros and cons to contact@marketbeat.com.

Moderna
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Moderna, Inc.:

  • The current stock price is around $25.14, which may present a buying opportunity for investors looking for value in the biotechnology sector.
  • Moderna, Inc. has shown resilience with a recent quarterly revenue of $142 million, exceeding analyst expectations, indicating strong operational performance.
  • Institutional investors hold a significant portion of the stock, with 75.33% of shares owned by such entities, suggesting confidence in the company's future prospects.
  • Analysts have a consensus rating of "Hold" with a target price of approximately $42.88, indicating potential upside for investors if the stock approaches this target.
  • Recent acquisitions by institutional investors, such as Banque Transatlantique SA increasing its stake by 60.4%, reflect growing confidence in the company's growth trajectory.

Moderna
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Moderna, Inc. for these reasons:

  • Moderna, Inc. reported a negative earnings per share (EPS) of -$2.13, which, while better than expected, still indicates ongoing financial challenges.
  • The company has a high price-to-earnings (P/E) ratio of -3.34, suggesting that it is currently unprofitable, which can be a red flag for potential investors.
  • Recent revenue decline of 41.1% compared to the same quarter last year raises concerns about the sustainability of its business model and market demand for its products.
  • Several analysts have issued "underperform" ratings, indicating skepticism about the stock's ability to perform well in the near term.
  • Market volatility, as indicated by a beta of 1.93, suggests that the stock may experience significant price fluctuations, which could be risky for investors.

MRNA Forecast - Frequently Asked Questions

According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for Moderna is $42.88, with a high forecast of $70.00 and a low forecast of $15.00.

24 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last twelve months. There are currently 4 sell ratings, 16 hold ratings, 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MRNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNA, but not buy additional shares or sell existing shares.

According to analysts, Moderna's stock has a predicted upside of 74.04% based on their 12-month stock forecasts.

Moderna has been rated by research analysts at Bank of America, Barclays, Citigroup, Cowen, Evercore ISI, JPMorgan Chase & Co., Leerink Partners, Morgan Stanley, and Wells Fargo & Company in the past 90 days.

Analysts like Moderna less than other "medical" companies. The consensus rating for Moderna is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MRNA compares to other companies.

Related Companies
Today's Ratings
Top-Rated Stocks
More Ratings Tools

This page (NASDAQ:MRNA) was last updated on 9/10/2025 by MarketBeat.com Staff
From Our Partners
Stunning new initiative unfolding in the White House?
what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...
Paradigm Press | Sponsoredtc pixel
Trump's Law S.1582: $21T Dollar Revolution Coming
Do you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...
Brownstone Research | Sponsoredtc pixel
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsoredtc pixel
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...
Porter & Company | Sponsoredtc pixel
World War 3? Everything Just Changed — and One Tiny Company Is at the Center of It.
Trump immediately activated a $5.3 TRILLION AI missile shield — code-named Golden Dome — to stop drone swarms ...
Angel Publishing | Sponsoredtc pixel
Time is running out on the most obvious trade in history
Gold just broke out to fresh all-time highs, silver is up 40% this year, and for the first time in three decad...
Golden Portfolio | Sponsoredtc pixel
“HELIOS”: My No. 1 Investment of the 2020s
A mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...
Stansberry Research | Sponsoredtc pixel
2013 Bitcoin miner reveals his trading system (free)
There are 18,347 cryptocurrencies in the market right now. 99% of them will fail. And trying to pick winner...
Crypto Swap Profits | Sponsoredtc pixel